Sign in to view content

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD

Robert L. Avery, MD

Video
Published 2025

Related

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Development of a Novel Retinal Tamponade Agent to Replace Fluorinated Gas and Silicone Oil
James A Stefater, MD, PhD
Annual Meeting Talks
2019
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more